Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Clinical trial NCT06970353 · RECRUITING

Trial details

NCT number: NCT06970353
Sponsor: Fudan University
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation Advanced PDTC or ATC With NRAS Mutation

Start date: 2025-05-27
Primary completion: 2026-12-30
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.